Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF TQB3122 "PARP1 INHIBITOR" ACCEPTED BY NMPA2025.08.11
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR PHASE II CLINICAL TRIAL ON LM-24C5 "CEACAM5/4-1BB BISPECIFIC ANTIBODY" APPROVED BY THE NMPA2025.08.07
-
VOLUNTARY ANNOUNCEMENT - ROVADICITINIB TABLET "JAK/ROCK INHIBITOR" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS2025.08.06
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINCAL TRIAL OF TQC3302 "ICS/LAMA/LABA SOFT MIST INHALATION FORMULATION" APPROVED BY NMPA2025.08.05
-
NOTIFICATION OF BOARD MEETING2025.08.01
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 20252025.08.01
-
VOLUNTARY ANNOUNCEMENT - LM-299 OUT-LICENSING COLLABORATION PROGRESSING SMOOTHLY; US$300 MILLION MILESTONE PAYMENT TO BE RECEIVED SHORTLY2025.07.30
-
VOLUNTARY ANNOUNCEMENT - IND APPROVAL FOR LM-350 "CDH17 ADC" FROM THE US FDA2025.07.24